Recipharm expands US sterile fill and finish capabilities for biologics
The multi-million-dollar investment enhances capacity for biologics and advanced therapies, following a clinical fill and finish agreement with a major pharma company.
See the latest news and media coverage for Recipharm. We track all announcements, press releases, and industry mentions in real time, all in one place.
CDMO for pharmaceuticals and biologics
recipharm.comLast updated
In short: Recipharm expanded its manufacturing capacity and biological capabilities while divesting its Israel unit to focus its global footprint.
The multi-million-dollar investment enhances capacity for biologics and advanced therapies, following a clinical fill and finish agreement with a major pharma company.
The funding supports development of NMR-based real-time PAT to monitor RNA vaccine CQAs, aiming to accelerate batch release, reduce costs and improve global vaccine access.
It highlights 20% Scope 1 and 74% Scope 2 emissions reductions, 100% renewable electricity, and strong CDP scores. They partner with customers to cut Scope 3 emissions.
Earned B for Climate Change, A- for Water Security, A for Supplier Engagement from CDP. Cut Scope 1 emissions 20%, Scope 2 74% vs 2021.
Private equity firm EQT announced on Monday a bid for contract manufacturer Recipharm. The prospects for the acquisition are good and the company's founders have already rallied behind the bid. EQT...
CDMO obtains both Vibalogics and Arranta Bio to increase presence in the sector...
Detailed price information for Scinai Immunotherapeutics Ltd ADR (SCNI-Q) from The Globe and Mail including charting and trades.
Recipharm Advanced Bio has closed its Boxborough facility and cut about 40% of its local workforce over the past year, consolidating operations in Watertown.
Track Recipharm and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Recipharm and other trending companies.